Advertisement

Topics

Eyenovia, Inc. Company Profile

19:47 EDT 21st October 2018 | BioPortfolio


News Articles [14 Associated News Articles listed on BioPortfolio]

Eyenovia announces positive results of EYN PG21 clinical trial

Eyenovia, a company developing a pipeline of ophthalmology products using its patented piezo-print technology, has announced positive results of its...Read More... The post Eyenovia announces positive...

Eyenovia to Participate in Panel Presentation at OSN New York 2018

NEW YORK, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology...

Eyenovia Reports Second Quarter 2018 Financial Results

NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology ...

Eyenovia to Present at the Ladenburg Thalmann 2018 Healthcare Conference

NEW YORK, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology...

Eyenovia to Present at the JMP Securities 2018 Life Sciences Conference

NEW YORK, June 11, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-pri...

Eyenovia to Present at the 20th Annual H.C. Wainwright Global Investment Conference

NEW YORK, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology ...

Eyenovia posts $5.1 million loss in 2017

Eyenovia reported a net loss of $2.2 million, or $0.84 per share, in the fourth quarter of 2017 compared with a net loss of $1.2 million, or $0.51 per share, in the fourth quarter of 2016, according t...

Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q2 2018 Results - Earnings Call Transcript

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Eyenovia MiDD Usability Study

This study is to evaluate the usability and patient tolerability for microtherapeutic dosing of commercially available ocular medication via the Eyenovia microdose delivery system (MiDD)

Companies [2 Associated Companies listed on BioPortfolio]

Eyenovia Inc.

Eyenovia is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for mic...

Eyenovia, Inc.

More Information about "Eyenovia, Inc." on BioPortfolio

We have published hundreds of Eyenovia, Inc. news stories on BioPortfolio along with dozens of Eyenovia, Inc. Clinical Trials and PubMed Articles about Eyenovia, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Eyenovia, Inc. Companies in our database. You can also find out about relevant Eyenovia, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record